(NP (NP (NP (NN Demonstration)) (PP (IN of) (NP (NP (DT a) (ADJP (NN 1,25-dihydroxyvitamin) (JJ D3-responsive)) (NN protein)) (PP (IN in) (NP (JJ human) (NNS lymphocytes))))) (: :)) (NP (NP-COOD (NP (JJ immunologic) (NN crossreactivity)) (CC and) (NP (JJ inverse) (NN regulation))) (PP (IN with) (NP (DT the) (NN vitamin) (NN D) (NN receptor)))) (. .))
(S (S-ADV (NP-SBJ (-NONE- *-25)) (VP (VBG Using) (NP (NP (NN Western) (NN blot) (NN analysis)) (PP (IN with) (NP (NP (DT a) (JJ monoclonal) (NN antibody)) (VP (VBG recognizing) (NP (NP (DT a) (NN 17-amino) (NN acid) (NN epitope)) (PP (IN of) (NP (DT the) (NP (NP (NN 1,25-dihydroxyvitamin) (NN D3)) (PRN (-LRB- -LCB-) (NP (NN 1,25-LRB-OH-RRB-2D3)) (-RRB- -RCB-))) (NN receptor)))))))))) (, ,) (NP-SBJ-25 (PRP we)) (VP (VBP have) (VP (VBN detected) (NP (CD two) (VBG crossreacting) (NNS proteins)) (PP (IN in) (NP (VBN activated) (JJ normal) (JJ human) (NNS lymphocytes))))) (. .))
(S (NP-SBJ-26 (NP (NP (DT The) (JJR smaller)) (PP (IN of) (NP (DT the) (CD two) (NNS proteins)))) (PRN (-LRB- -LRB-) (NP (CD 50) (NN kDa)) (-RRB- -RRB-))) (VP-COOD (VP (VBD was) (ADJP-PRD (JJ indistinguishable) (PP (IN from) (NP (DT the) (JJ classical) (NN 1,25-LRB-OH-RRB-2D3) (NN receptor))))) (CC and) (, ,) (VP (S-ADV (NP-SBJ (-NONE- *-27)) (ADJP-PRD (JJ similar) (PP (TO to) (NP (DT the) (JJ classical) (NN 1,25-LRB-OH-RRB-2D3) (NN receptor))) (, ,))) (VBD was) (VP (VBN upregulated) (NP-27 (-NONE- *-26)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion))) (PP (IN by) (NP-LGS (NN 1,25-LRB-OH-RRB-2D3)))))) (. .))
(S (NP-SBJ-28 (DT The) (JJR larger) (VBG crossreacting) (NN protein)) (VP-COOD (VP (VBD exhibited) (NP (NP (DT an) (JJ electrophoretic) (NN mobility)) (PP (IN of) (NP (CD 80) (NN kDa))))) (, ,) (VP (VBD was) (VP (JJ localized) (NP (-NONE- *-28)) (PP (IN in) (NP (DT the) (NN cell) (NN cytosol))))) (, ,) (CC and) (VP (VBD appeared) (S (NP-SBJ (-NONE- *-28)) (VP (TO to) (VP (VB be) (ADJP-PRD (JJ specific) (PP (IN for) (NP (VBN activated) (NNS lymphocytes)))) (SBAR (IN since) (S (NP-SBJ-29 (PRP it)) (VP (VBD was) (RB not) (VP (VBN detected) (NP (-NONE- *-29)) (PP (IN in) (NP (NP (JJ several) (JJ other) (JJ human) (NNS cells)) (PP (VBG including) (NP (NNS monocytes)))))))))))))) (. .))
(S (S (ADVP (RBR More) (RB strikingly)) (, ,) (NP-SBJ-30 (DT the) (JJ 80-kDa) (NN protein)) (VP (VBD was) (VP (VBN downregulated) (NP (-NONE- *-30)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion))) (PP (IN by) (NP-LGS (NN 1,25-LRB-OH-RRB-2D3))))) (: ;)) (S (NP-SBJ (DT this) (NN effect)) (VP (VBD was) (ADJP-PRD-COOD (ADJP (JJ independent) (PP (IN of) (NP (NP (DT the) (NN mode)) (PP (IN of) (NP (NN lymphocyte) (NN activation)))))) (CC and) (ADJP (JJ specific) (PP (IN for) (NP (NP (DT the) (NN 1,25-LRB-OH-RRB-2D3) (NN metabolite)) (PP (IN of) (NP (NN vitamin) (NN D3)))))))) (. .)))
(S (ADVP (RB However)) (, ,) (NP-SBJ (NP (CD two) (JJ potent) (JJ immunosuppressive) (NNS agents)) (, ,) (NP-COOD (NP (NNS glucocorticoids)) (CC and) (NP (NN cyclosporin) (DT A))) (, ,)) (ADVP (RB also)) (VP (VBD inhibited) (NP (DT the) (JJ 80-kDa) (NN protein))) (. .))
